Phenotypes associated with this allele

• Allele Symbol: Avpr2^tm2.1Jwe
• Allele Name: targeted mutation 2.1, Jurgen Wess
• Allele ID: MGI:7282271
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Avpr2^tm2.1Jwe/Y Tg(CAG-cre/Esr1*)5Amc/0	involves: 129 * C57BL/6	MGI:7282305

Genotype
MGI:7282305

cn1

• Allelic Composition: Avpr2^tm2.1Jwe/Y; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: 129 * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

polydipsia ( J:324922 )

♂ • 7- to 8-week-old males treated with tamoxifen for 6 days show an increase in water intake

♂ • treatment with the selective EP4 receptor agonist ONO results in a 50% decrease in cumulative water consumption

renal/urinary system

decreased urine creatinine level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine creatinine concentration

decreased urine potassium level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine potassium concentration

decreased urine sodium level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine sodium concentration

♂ • however, serum sodium levels are normal

decreased urine osmolality ( J:324922 )

♂ • urine produced by tamoxifen-treated males has very low osmolality

♂ • urine osmolality is lower by about 25% even prior to tamoxifen treatment

♂ • treatment with 1-desamino-8-D-AVP, a selective AVPR2 agonist, is unable to increase urine osmolality in tamoxifen-treated mice

♂ • treatment with the selective EP4 receptor agonist ONO leads to dose-dependent increases in urine osmolality in tamoxifen-administered mice

decreased urine urea nitrogen level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine urea

hydronephrosis ( J:324922 )

♂ • kidneys show distention of the renal pelvis after tamoxifen treatment

♂ • ONO treatment completely prevents further expansion of renal pelvic space in tamoxifen-administered mice

decreased renal glomerular filtration rate ( J:324922 )

♂ • tamoxifen-treated males show an approximate 40% reduction of glomerular filtration rate

♂ • ONO treatment restores normal glomerular filtration rate in tamoxifen-administered mice

polyuria ( J:324922 )

♂ • 7- to 8-week-old males treated with tamoxifen for 6 days show an increase in urine production

♂ • treatment with the selective EP4 receptor agonist ONO leads to a reduction in urine output in tamoxifen-administered mice

homeostasis/metabolism

decreased urine creatinine level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine creatinine concentration

decreased urine potassium level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine potassium concentration

decreased urine sodium level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine sodium concentration

♂ • however, serum sodium levels are normal

decreased urine osmolality ( J:324922 )

♂ • urine produced by tamoxifen-treated males has very low osmolality

♂ • urine osmolality is lower by about 25% even prior to tamoxifen treatment

♂ • treatment with 1-desamino-8-D-AVP, a selective AVPR2 agonist, is unable to increase urine osmolality in tamoxifen-treated mice

♂ • treatment with the selective EP4 receptor agonist ONO leads to dose-dependent increases in urine osmolality in tamoxifen-administered mice

decreased urine urea nitrogen level ( J:324922 )

♂ • tamoxifen-treated males show a reduction in urine urea

growth/size/body

decreased body weight ( J:324922 )

♂ • tamoxifen-treated males weigh approximately 25% less than controls

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
X-linked nephrogenic diabetes insipidus		DOID:0081060	OMIM:304800	J:324922